Becton, Dickinson and Company (NYSE:BDX) Research Coverage Started at UBS Group

UBS Group started coverage on shares of Becton, Dickinson and Company (NYSE:BDX) in a research report released on Tuesday, MarketBeat reports. The firm issued a buy rating and a $190.00 target price on the medical instruments supplier’s stock.

A number of other brokerages have also commented on BDX. Bank of America lowered their price objective on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a research note on Tuesday, April 14th. Zacks Research upgraded shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. TD Cowen dropped their price target on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research note on Monday, May 4th. Finally, Barclays increased their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $180.93.

Becton, Dickinson and Company Stock Down 1.7%

Shares of BDX opened at $165.59 on Tuesday. The firm has a market capitalization of $45.63 billion, a price-to-earnings ratio of 41.92, a PEG ratio of 12.00 and a beta of 0.21. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The business’s fifty day moving average price is $151.48 and its two-hundred day moving average price is $163.63. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. During the same period last year, the firm earned $3.35 EPS. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, analysts predict that Becton, Dickinson and Company will post 12.53 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is 106.33%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,189 shares of company stock valued at $765,661 in the last three months. 0.40% of the stock is owned by insiders.

Institutional Trading of Becton, Dickinson and Company

A number of institutional investors have recently modified their holdings of the company. Northside Capital Management LLC grew its holdings in shares of Becton, Dickinson and Company by 18.3% during the second quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock worth $9,280,000 after buying an additional 9,494 shares in the last quarter. Cardinal Capital Management Inc. lifted its stake in Becton, Dickinson and Company by 6.6% in the 2nd quarter. Cardinal Capital Management Inc. now owns 178,421 shares of the medical instruments supplier’s stock valued at $27,000,000 after acquiring an additional 11,039 shares in the last quarter. Tema ETFs LLC lifted its stake in Becton, Dickinson and Company by 9.5% in the 2nd quarter. Tema ETFs LLC now owns 5,006 shares of the medical instruments supplier’s stock valued at $758,000 after acquiring an additional 435 shares in the last quarter. Canvas Wealth Advisors LLC boosted its position in Becton, Dickinson and Company by 15.8% during the 2nd quarter. Canvas Wealth Advisors LLC now owns 1,580 shares of the medical instruments supplier’s stock worth $239,000 after acquiring an additional 215 shares during the last quarter. Finally, Handelsbanken Fonder AB grew its stake in shares of Becton, Dickinson and Company by 32.7% during the 2nd quarter. Handelsbanken Fonder AB now owns 170,572 shares of the medical instruments supplier’s stock worth $25,813,000 after acquiring an additional 42,040 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.